Photo by robertbye from unsplash
The cardiovascular community has been debating for decades whether to treat mild-tomoderate hypertriglyceridemia. Results of the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT)1 position this controversy as front… Click to show full abstract
The cardiovascular community has been debating for decades whether to treat mild-tomoderate hypertriglyceridemia. Results of the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT)1 position this controversy as front matter for deliberation. For lipid experts, dominating the discourse will be the strength of experimental evidence, mechanism of benefit, identification of treatment response parameters, and prioritizing treatment options. For the practitioner, the question ultimately will be whether potential gains are worth the disruption to clinical care that accompanies a new paradigm in prevention.
Journal Title: Circulation
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!